<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article article-type="research-article"><?properties open_access?><!-- Original-type: ra--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Cancer</journal-id><journal-title>British Journal of Cancer</journal-title><issn pub-type="ppub">0007-0920</issn><issn pub-type="epub">1532-1827</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">10901362</article-id><article-id pub-id-type="pmc">2363476</article-id><article-id pub-id-type="pii">6691192</article-id><article-id pub-id-type="doi">10.1054/bjoc.2000.1192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Regular Article</subject></subj-group></article-categories><title-group><article-title>Phase I study of irinotecan and raltitrexed in patients with advanced astrointestinal tract adenocarcinoma</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ford</surname><given-names>H E R</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Cunningham</surname><given-names>D</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ross</surname><given-names>P J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Rao</surname><given-names>S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Aherne</surname><given-names>G W</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Benepal</surname><given-names>T S</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Price</surname><given-names>T</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Massey</surname><given-names>A</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Vernillet</surname><given-names>L</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Medicine and Gastrointestinal Unit, Royal Marsden NHS Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK</aff><aff id="aff2"><label>2</label>CRC Centre for Cancer Therapeutics, Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, UK</aff><aff id="aff3"><label>3</label>Rh&#x000f4;ne-Poulenc R&#x000e9;cherche et Developement, Antony Cedex, France</aff><pub-date pub-type="epub"><day>15</day><month>06</month><year>2000</year></pub-date><pub-date pub-type="ppub"><month>07</month><year>2000</year></pub-date><volume>83</volume><issue>2</issue><fpage>146</fpage><lpage>152</lpage><history><date date-type="received"><day>11</day><month>11</month><year>1999</year></date><date date-type="rev-recd"><day>15</day><month>02</month><year>2000</year></date><date date-type="accepted"><day>24</day><month>02</month><year>2000</year></date></history><copyright-statement>Copyright 2000, Cancer Research Campaign</copyright-statement><copyright-year>2000</copyright-year><permissions><copyright-holder>Cancer Research Campaign</copyright-holder></permissions><abstract><p>To determine the dose-limiting toxicities (DLT) and maximum tolerated dose (MTD) of irinotecan and raltitrexed given as sequential short infusions every 3 weeks, 33 patients with pretreated gastrointestinal adenocarcinoma (31 colorectal, 2 oesophagogastric) entered this open label dose-escalation study. For the first five dose levels patients received irinotecan 175&#x02013;350 mg m<sup>&#x02013;2</sup>followed by raltitrexed 2.6 mg m<sup>&#x02013;2</sup>. Level VI was irinotecan 350 mg m<sup>&#x02013;2</sup>plus raltitrexed 3.0 mg m<sup>&#x02013;2</sup>, level VII was irinotecan 400 mg m<sup>&#x02013;2</sup>plus raltitrexed 2.6 mg m<sup>&#x02013;2</sup>; 261 courses were administered. Only one patient at dose levels I&#x02013;V experienced DLT. At level VI, 5/12 patients experienced DLT: one had grade 3 diarrhoea and lethargy, one had grade 4 diarrhoea and one had lethargy alone. Two others had lethargy caused by disease progression. There was no first-cycle neutropenia. At level VII, 3/6 patients experienced dose-limiting lethargy, one also had grade 3 diarrhoea. Dose intensity fell from over 90&#x00025; for both drugs at level VI to 83&#x00025; for irinotecan and 66&#x00025; for raltitrexed at level VII. Lethargy was therefore the DLT, and level VII the MTD. Pharmacokinetic data showed no measurable drug interaction; 6/30 patients (20&#x00025;) had objective responses. This combination is active with manageable toxicity. Recommended doses for further evaluation are irinotecan 350 mg m<sup>&#x02013;2</sup>and raltitrexed 3.0 mg m<sup>&#x02013;2</sup>. &#x000a9; 2000 Cancer Research Campaign</p></abstract><kwd-group><kwd>irinotecan</kwd><kwd>raltitrexed</kwd><kwd>drug combination</kwd><kwd>phase I</kwd><kwd>pharmacokinetics</kwd></kwd-group></article-meta></front></article>


